Combination products

With weeks remaining until the FDA’s new cGMP rules kick in, many drug, biologics, and device manufacturers remain unclear about how to comply.

As the trend toward self-administration continues, the need for careful consideration of primary container design and interaction with biologics, devices, and the patient becomes more critical.

Nanotechnology, combination products, and regulatory strategies frame the future in medical compliance issues, as noted in Feb. 12 MD&M West conference track.

Temperature-controlled distribution involves multiple variables, as discussed here with Geoffrey Glauser, vaccine and therapeutic supply chain contractor and subject-matter expert with Conceptual Mindworks, Inc.